DigestRedComo funciona
Red
/
Empresas
AA
No verificado

AAVantgarde

Sobre qué escribimos

Anuncios brevesBiotecnologíaFinanzasLegislación/Derecho/FiscalidadMedicina Salud Bienestar

11 Comunicados de prensa

Ver todos los comunicados de prensa
15/01/2026
Biotecnología
AAVantgarde Completes Enrollment in LUCE-1 Phase 1/2 Clinical Trial of AAVB-081 for Usher Syndrome Type B-associated Retinitis Pigmentosa
Fuente
AAVantgarde
Editor
GLOBENEWSWIRE
1.00
0
08/01/2026
Biotecnología
AAVantgarde to Present at the 44th Annual J.P. Morgan Healthcare Conference
Fuente
AAVantgarde
Editor
GLOBENEWSWIRE
1.00
0
03/11/2025
Biotecnología
Finanzas
AAVantgarde Closes $141 Million Series B Financing to Advance its Clinical Programs in Stargardt Disease and Usher 1B Syndrome
Fuente
AAVantgarde
Editor
GLOBENEWSWIRE
1.00
0
07/10/2025
Biotecnología
AAVantgarde announces 3 presentations at ESGCT 2025 annual meeting
Fuente
AAVantgarde
Editor
GLOBENEWSWIRE
1.00
0
02/10/2025
Biotecnología
Medicina Salud Bienestar
Legislación/Derecho/Fiscalidad
Anuncios breves
AAVantgarde Announces FDA Orphan Drug Designation and UK CTA approval for AAVB-039 for the Treatment of Stargardt Disease
Fuente
AAVantgarde
Editor
GLOBENEWSWIRE
1.00
0
05/09/2025
Biotecnología
Medicina Salud Bienestar
AAVantgarde presents updated positive clinical data from its AAVB-081 program for Usher 1B at EURetina 2025
Fuente
AAVantgarde
Editor
GLOBENEWSWIRE
1.00
0
28/08/2025
Biotecnología
Medicina Salud Bienestar
AAVantgarde to Present Updated Clinical Data from LUCE-1 Study at EURetina 2025
Fuente
AAVantgarde
Editor
GLOBENEWSWIRE
1.00
0
12/08/2025
Biotecnología
Anuncios breves
AAVantgarde Bio Announces FDA Fast Track Designation for AAVB-039 for the Treatment of Stargardt Disease
Fuente
AAVantgarde
Editor
GLOBENEWSWIRE
1.00
0
15/07/2025
Biotecnología
Medicina Salud Bienestar
AAVantgarde Receives FDA Clearance to Progress Stargardt Disease Asset, AAVB-039, into CELESTE, a Phase 1/2 Clinical Trial
Fuente
AAVantgarde
Editor
GLOBENEWSWIRE
1.00
0
12/05/2025
Biotecnología
AAVantgarde presents positive clinical data from its AAVB-081 program for Usher 1B and preclinical data from its AAVB-039 program for Stargardt at the ARVO 2025 annual meeting
Fuente
AAVantgarde
Editor
GLOBENEWSWIRE
1.00
0

Detalles de contacto

Redes sociales

Seguidores
0
Compatibilidad
0